People · Operator
Named in public records as an officer, director or promoter · active 2023–2023 · Pharmaceuticals
| Company | Role | Sector | Stage | Raised · real | Value · est | Tied |
|---|---|---|---|---|---|---|
| UroGen Pharma Ltd. | — | Pharmaceuticals | Series D+ | $120.0M | $1.7B | 2023 |
Mark A. Schoenberg, M.D. at the center, the companies they're named on, and every other operator named alongside them — an interlock map of shared founding teams, boards and funds. Name-matched, so treat as a research lead.
People named alongside Mark A. Schoenberg, M.D. on the same companies — an interlock signal (shared founding team, board, or fund). Name-matched, so verify before acting.
| Operator | Shared | Their companies |
|---|---|---|
| Cynthia Butitta | 1 | 3 |
| Ran Nussbaum | 1 | 3 |
| Dan Wildman | 1 | 2 |
| Jason A. Smith | 1 | 1 |
| Arie Belldegrun, M.D. | 1 | 1 |
| Stuart Holden, M.D. | 1 | 1 |
| Fred Cohen, M.D. | 1 | 1 |
| Don Kim | 1 | 1 |
| James A. Robinson, Jr. | 1 | 1 |
| Elizabeth Barrett | 1 | 1 |
| Leana Wen, M.D., MSc | 1 | 1 |
People are matched by normalized name across records; a common name may merge distinct individuals. Treat as a research lead, the same way modeled valuations are directional, not quoted.